A promising new once-daily oral pill from Eli Lilly, known as orforglipron, has shown superior results compared to the existing oral version of semaglutide (Rybelsus) in a major head-to-head clinical trial. This small-molecule GLP-1 receptor agonist could offer a more convenient and potentially more effective non-injectable option for people managing type 2 diabetes and seeking weight loss, addressing one of the key limitations of current treatments like Ozempic and Wegovy, which are typically administered via injection.
Strong Performance in the ACHIEVE-3 Phase 3 Trial
The ACHIEVE-3 trial, published in The Lancet in February 2026, involved 1,698 adults with type 2 diabetes whose blood sugar was inadequately controlled on metformin alone. Participants were randomized to receive either orforglipron (at 12 mg or 36 mg doses) or oral semaglutide (at 7 mg or 14 mg doses) for 52 weeks, with gradual dose escalation to improve tolerability.
Key results included:
- Blood sugar control (A1C reduction): Orforglipron 36 mg reduced A1C by an average of 1.91% to 2.2%, compared to 1.47% with oral semaglutide 14 mg. The 12 mg dose of orforglipron also outperformed both doses of semaglutide. Both orforglipron doses met the criteria for non-inferiority and demonstrated statistical superiority across primary and key secondary endpoints.
- Weight loss: With an average starting body weight of about 97 kg (214 lbs), participants on orforglipron 36 mg lost approximately 9.2% of their body weight (around 19.7 lbs or 8.9 kg). This compared to 5.3% (about 11 lbs or 5 kg) with oral semaglutide 14 mg — representing a 73% greater relative weight reduction. The 12 mg dose of orforglipron also delivered stronger weight loss than semaglutide.
- Additional benefits: Orforglipron showed improvements in cardiometabolic markers, including greater reductions in systolic blood pressure, triglycerides, and non-HDL cholesterol compared to oral semaglutide.
The trial highlighted another practical advantage: unlike oral semaglutide, which requires strict fasting and limited water intake around dosing, orforglipron can be taken more flexibly without such restrictions. This could improve long-term adherence for many patients.
How Orforglipron Fits in the Broader GLP-1 Landscape
GLP-1 receptor agonists like semaglutide (found in Ozempic, Wegovy, and Rybelsus) work by mimicking a gut hormone to reduce appetite, slow gastric emptying, and improve insulin response, leading to significant weight loss and better glycemic control. Injectable versions of semaglutide often achieve higher average weight loss (10–15% or more in dedicated obesity studies) than the oral form due to better bioavailability.
Orforglipron, as a true small-molecule drug, aims to combine the convenience of a daily pill with stronger efficacy than existing oral options. In separate obesity-focused trials (without diabetes), the 36 mg dose achieved up to about 11–12% weight loss over 72 weeks when combined with lifestyle changes, with a substantial portion of participants reaching 10%, 15%, or even 20% reductions.
Other oral candidates are also advancing. Novo Nordisk’s amycretin, a dual GLP-1 and amylin agonist, showed impressive early results — including up to 13–14% weight loss in shorter phase 2 studies — but it remains earlier in development compared to orforglipron’s phase 3 data.
Important Considerations and Next Steps
While the results are encouraging, orforglipron is not yet approved for widespread use. Eli Lilly has submitted the drug for regulatory review in multiple countries, with a potential U.S. FDA decision on obesity as early as April 2026 and plans for a diabetes indication later in the year. The company is preparing for launch, including building pre-approval inventory to help avoid supply issues seen with earlier GLP-1 drugs.
Common side effects align with the GLP-1 class, primarily gastrointestinal issues such as nausea, which were mostly mild to moderate. Discontinuation rates due to adverse events were somewhat higher with orforglipron than with oral semaglutide in the trial, though overall tolerability was considered acceptable.
As with all weight-loss medications, orforglipron works best alongside diet, exercise, and behavioral changes. Significant weight loss can also involve some muscle loss, so incorporating resistance training and adequate protein intake is often recommended. These drugs are not suitable for everyone and carry contraindications; long-term cardiovascular outcome data and sustained effectiveness beyond the trial periods will provide further clarity.
For individuals in regions like India, where access to newer GLP-1 therapies may evolve with global approvals, currently available options (including oral semaglutide where approved) remain important while awaiting potential new entries.
This development signals a shift toward more convenient oral alternatives in the growing field of incretin-based therapies, potentially expanding options for millions managing obesity and type 2 diabetes. Consult a healthcare provider for personalized advice, as individual responses vary and these treatments require medical supervision.
About The Author
